TGFB1 and neoplasm: I.e., αvβ8 blocking antibodies or specific depletion of integrin αvβ8 from the surface of CD4+CD25+ regulatory T cells could attenuate TGFβ mediated inhibition of CD8+ T cells and thereby restore tumor killing capacity of CD8+ T cells and synergizing with radio- or immune therapy (Dodagatta-Marri et al., 2021).